- 16 Rothman SM. Synaptic release of excitatory amino acid neurotransmitter mediates anoxic neuronal death. *Biochem Pharmacol* 1984;4:1884–91.
- mediates anoxic neuronal death. Biochem Finalmacol. 1704;4:1007-21.

 17 Olney W. Brain lesion, obesity and other disturbances in mice treated with monosodium glutamate. Science 1969;164:719-21.

 18 Albert A. Xenobiosis. Food, drugs and poisons in the human body. London: Chapman and Hall, 1987.

 10 Williams P.T. Description mechanisms, 2nd ed. New York, Wiley and
- 19 Williams RT. Detoxification mechanisms, 2nd ed. New York, Wiley and
- Williams R1. Detoxification mechanisms, 2nd ed. New York, Wiley and Sons, 1959.
 Jenner P, Testa B (eds). Concepts in Drug Metabolism. New York; Marcel Dekker, 1980.
 Klaasen CD, Rozman K. Adsorption, distribution and excretion of toxicants. In: Amdur MO, Doull J, Klaasen CD, eds. Toxicology, the basic science of poisons 4th ed. New York: Pergamon Press, 1991;50–87.
 Peters RA. Lethal synthesis (Croonian lecture). Proc R Soc Lond (Biol) 1952;139:10-170
- 1952:139:10-170.
- 23 Gonzalez FJ. The molecular biology of cytochrome P450s. Pharmacol Rev 1988:40:243.
- 24 Nebert DW, Jaiswal AK, Meyer UA, Gonzalez FJ. Human P-450 genes: evolution, regulation and possible role in carcinogenesis. *Biochem Soc Trans* 1988;15:586-9.
- Motulsky AG. Pharmacogenetics. Prog Med Genet 1964;3:49.
 Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL. Polymorphic
- hydroxylation of debrisoquine in man. Lancet 1977;ii:584-6.
 Weber WW, Hein DW. N-Acetylation pharmacogenetics. Pharmacol Rev 1985:37:25
- 28 Konradi C, Ozelius L, Breakefield XO. Highly polymorphic (GT)_n repeat sequence in Intron II of the human MAOB gene. *Genomics*, 1992;12: 176-7.
- 176-7.
 Price RA, Keith RA, Spielman RS. Major gene polymorphism for human erythrocyte thiol methyl transferase. *Genet Epidemiol* 1989;6:651-62.
 Rosen DR, Siddique T, Patterson D, *et al.* Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. *Nature* 1993;362:59-62.
 Bock KW. Metabolic polymorphisms affecting activation of toxic and mutagenic arylamines. *TIPS* 1992;13:223-6.
 Diray Y. Coop. MI. Parifection and characterization of two unique forms.
- Ding X, Coon MJ. Purification and characterization of two unique forms of cytochrome P-450 from rabbit nasal microsomes. *Biochemistry* 1988;27:8330.
- 33 Smith CAD, Gough AC, Leigh PN, et al. Debrisoquine hydroxylase gene

- polymorphism and susceptibility to Parkinson's disease. Lancet 1992; 339:1375-7.
- 339:13/3-7.
 34 Kondo I, Kanazawa I. Association of Xba I allele (Xba I 44kb) of the human cytochrome P-450dbI (CYP2D6) gene in Japanese patients with idiopathic Parkinson's disease. In: Nagatsu T, Narabayashi H, Yoshida M, eds. Key topics in brain research: Parkinson's disease. From clinical aspects to molecular basis, New York: Springer-Verlag, 1991;

- 111-7.
 35 Green S, Buttrum S, Molloy H, et al. N-methylation of pyridines in Parkinson's disease. Lancet 1991;338:120-1.
 36 Humphry CDN, Steventon GB, Sturman SG, Waring RH, Griffiths B, Williams AC. Monoamine oxidase substrates in Parkinson's disease. Biochem Pharmacol 1990;11:2562-4.
 37 Bonuccelli U, Piccini P, Del Dotto P, Pacifici GM, Corsini GU, Muratorio A. Platelet monoamine oxidase B activity in Parkinsonian patients. J Neurol Neurosurg Psych 1990;53:854-5.
 38 Chiba K, Trevor A, Castagnoli N Jr. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commonu 1984;120:574-8.
 39 The Parkinson Study Group. Effect of deprenyl on the progression of dis-
- The Parkinson Study Group. Effect of deprenyl on the progression of dis-
- ability in early Parkinson's disease. N Eng J Med 1989;322:1364—71.
 Widner H, Tetrud J, Rehncrona S, et al. Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). New Eng J Med 1992;327: 1556-61
- Steventon G, Heafield MTE, Waring RH, Williams AC. Xenobiotic metabolism in Parkinson's disease. *Neurology* 1989;39:883-7.
 Steventon G, Williams AC, Waring RH, Pall HS, Adams D. Xenobiotic
- 43 Heafield MTE, Fearn S, Steventon GB, Waring RH, Williams AC, Sturman SG. Plasma cysteine and sulphate levels in patients with motor neurone Parkinson's and Alzheimer's disease. Neurosci Lett 1990;110:
- 44 Heafield MTE, Waring RH, Sturman SG, Steventon GB, Williams AC Thompson H. N-Acetylation status in neurodegenerative disease. Med Sci Res 1990;18:963-4.
- 45 Waring RH, Steventon G, Heafield MTE, Sturman SG, Williams AC, Smith M. S-methylation in Parkinson's disease and motor neurone disease. Lancet 1989;ii:356-7.

Neurological stamp

Philippe Pinel (1745-1826)

When Philippe Pinel was physician to the Hospice de Bicêtre, the Paris asylum for men, he authorised removal of the chains that restrained the patients. The uncontrolled behaviour of the men, that others had predicted, did not occur.

Pinel was convinced that insane people needed treatment and were not possessed by a devil. His theory that insanity was a mental illness was not received favourably by the medical profession. His influence, however, led to a far more enlightened approach to the treatment of those that were mentally ill.

In 1801 Pinel published a full account of his new techniques in his Traité Médeco-Philosophique sur l'aliénation mentate ou la manie (Medico-Philosophical Treatise on Mental Alienation of Mania). Three years earlier he had published Nosographie Philosophique which was an attempt to classify diseases in the way Linnaeus had earlier classified animals.

This stamp was issued in 1958 as part of a set honouring French doctors (Stanley Gibbons 1367, Scott 865).

L F HAAS

